Posts filtered by tags: Life Sciences[x]


 

Thermo Bags Brammer For $1.7B as Gene Therapy Deal Spree Continues

Thermo Fisher Scientific late Sunday evening agreed to buy Brammer Bio for $1.7 billion, yet another bet by a large biopharmaceutical organization on the future of gene therapy.Thermo (NYSE: TMO), a Waltham, MA, developer of lab equipment, made an all-cash offer for Cambridge, MA-based Brammer, a contract manufacturer of gene therapy delivery tools known as viral “vectors.”In a gene therapy procedure, these vectors—engineered viruses—are filled with genetic blueprints and infused into a patient...
Tags: Boston, Boston blog main, Boston top stories, National blog main, National top stories, New York blog main, New York top stories, Biogen, Biotech, Brammer Bio, Clinical Trials, Deals, FDA, Gene Therapy, Hemophilia, Johnson & Johnson


CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M

The high-stakes race to use CRISPR gene editing technology to create medicines has been underway for years now, and human trials are just starting. But the idea of using CRISPR as a tool to detect and diagnose a disease has been gaining traction, too, and the launch of a new startup today called Sherlock Biosciences marks the latest step.Sherlock has been formed around technologies licensed from the Broad Institute of MIT and Harvard University, dubbed “SHERLOCK” and “INSPECTR,” respectively, t...
Tags: Deals, Startups, Boston, Trends, Vc, Harvard University, Sherlock, Crispr, Illumina, Life Sciences, Jim Collins, Broad Institute of MIT, Jennifer Doudna, Gene Editing, Feng Zhang, David Walt


Flagship Reloads With $824M For Latest Growth Capital Fund

Flagship Pioneering, one of the Boston area’s top biotech company creators, has closed a new $824 million fund to help fuel the growth of its startups.The new fund—Special Opportunities Fund II—will complement the cash the firm uses to start its companies, much like the $285 million “Special Opportunities” fund the firm announced in 2016. In a statement, Flagship CEO Noubar Afeyan said the fund will provide “new capital to grow platform companies”—that is, startups based not on a single asset, ...
Tags: Deals, Startups, Boston, Trends, Vc, Life Sciences, Cambridge MA, Atlas Venture, National blog main, Boston blog main, Boston top stories, Denali Therapeutics, Noubar Afeyan, Moderna, Evelo Biosciences, Flagship Pioneering


Pfizer Bolsters Gene Therapy Position with $51M Vivet Deal

Pfizer this morning added to its methodical push into the gene therapy field, paying $51 million for a small stake in Vivet Therapeutics and the option to buy the Parisian biotech in the future.The deal is the latest in a recent string of investments by large biopharma companies in gene therapy, which offers the potential for a long-lasting, if not permanent effect through a one-time treatment. The field has gone through decades of ups and downs, but has now proven that it can develop approved ...
Tags: Deals, New York, Trends, Pfizer, Biotech, Life Sciences, Roche, Biogen, Gene Therapy, National blog main, New York blog main, New York top stories, Boston blog main, Spark Therapeutics, Rare diseases, Duchenne Muscular Dystrophy


The Role of the Student Engineer in Medicine and Innovation

The last 50 years have seen many great technical advances in medical treatments, ranging from drug delivery and imaging to skin grafts and prosthetics. These advances—both large and small—have drawn on many fields and have transformed patient care.When examining the current state of clinical technology, the focus is naturally on the technology and its outcomes, rather than the process that led to that breakthrough. It is a popular notion that such advances are the result of “eureka moments” by i...
Tags: Startups, Education, Trends, Engineering, Healthcare, Innovation, Wisconsin, Cisco Systems, Warf, Life Sciences, Healthtech, Biomedical Engineering, Morgridge Institute for Research, Boston Xcon, Boulder/Denver Xcon, Detroit Xcon


Bio Roundup: Golumbeski’s Legacy, CRISPR Moratorium, Rebate Week & More

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb’s proposal to buy Celgene for $74 billion, it wasn’t that long ago that another company’s gaze was fixed on the Summit, NJ, drug maker.In the early 2000s, before the FDA approved Celgene’s flagship multiple myeloma drug lenalidomide (Revlimid), Novartis (NYSE: NVS considered buying the company. It passed, unwilling to risk billions on an unapproved drug. Those details came from biopharma dealmaker George...
Tags: Deals, Startups, China, Ipo, Cancer, Trends, Investing, Merck, Colorectal Cancer, Multiple Sclerosis, Harvard University, Health Insurance, Astrazeneca, Center For Medicare And Medicaid Services, Fda, National


XGenomes is bringing DNA sequencing to the masses

As healthcare moves toward genetically tailored treatments, one of the biggest hurdles to truly personalized medicine is the lack of fast, low-cost genetic testing. And few people are more familiar with the problems of today’s genetic diagnostics tools than Kalim Mir, the 52-year-old founder of XGenomes, who has spent his entire professional career studying the human genome. “ Ultimately genomics is going to be the foundation for healthcare,” says Mir. “For that we need to move toward a sequenci...
Tags: TC, Y Combinator, England, Biology, Tech, Harvard, United States, United Kingdom, Healthcare, Genome, Yorkshire, Lasers, Genomics, Human Genome Project, Northern England, Biotechnology


WI Watchlist: Foxconn Fund, UW Accelerator, MSOE A.I. Hall & More

It’s time to catch up on Wisconsin innovation news:—Jason Franklin will manage the Wisconn Valley Venture Fund, a $100 million fund formed last August by Foxconn Technology Group and three leading Wisconsin businesses and organizations: Advocate Aurora Health, Northwestern Mutual, and Johnson Controls (NYSE: JCI). Foxconn, a Taiwanese manufacturing giant, has said it’s building a massive (and controversial) electronics factory in southeastern Wisconsin.Franklin is a University of Wisconsin-Madi...
Tags: Deals, Startups, Education, Trends, Tech, It, Vc, Software, Healthcare, Nvidia, Wisconsin, Silicon Valley, Andreessen Horowitz, Cleantech, Foxconn, Life Sciences


Mammoth Biosciences adds the final piece of the CRISPR diagnostics puzzle to its toolkit

With the announcement today that Mammoth Biosciences has received the exclusive license from the University of California, Berkeley to the new CRISPR protein Cas14, the company now has the last piece of its diagnostics toolkit in place. Cas14 is a newly discovered protein from the lab of Jennifer Doudna, a pioneer in gene-editing research and a member of the first research team to identify and unlock the power of CRISPR technology. Doudna and Mammoth Biosciences co-founder Lucas Harrington we...
Tags: TC, Biology, California, Dna, Tech, Walgreens, HPV, Flu, Illness, University Of California Berkeley, Berkeley, University Of California, Cvs, Crispr, Biotechnology, Life Sciences


X4 Completes Reverse Merger with Arsanis, Looks Ahead to Phase 3 Test

X4 Pharmaceuticals is the latest biotech to join the public markets, but it didn’t follow the IPO path to get there.Cambridge, MA-based X4 said Wednesday that it completed its “reverse merger” with Arsanis (NASDAQ: ASNS). Such business combinations enable a privately held company to go public by merging with a publicly traded business. Shares of the new X4 are set to begin trading on the Nasdaq exchange Thursday under the stock symbol “XFOR.”X4 is developing drugs that target the CXCR4 pathway,...
Tags: Deals, Drugs, Ipo, Boston, Trends, Cambridge, Biotech, Nasdaq, Life Sciences, Genzyme, National blog main, Boston blog main, Boston top stories, National Organization for Rare Disorders, X4 Pharmaceuticals, X4


Connect, Longtime Local Accelerator, Names Silvia Mah as President

Connect, a 34-year-old nonprofit which runs the well-known Springboard Accelerator Program for startups, announced Monday that it had tapped Silvia Mah, a San Diego investor and entrepreneur, as its new president.She succeeds Greg McKee, who served as president and CEO of the San Diego-based organization for five years before stepping down last month to start a venture capital fund.Mah is executive director of Hera Labs, an accelerator program for women-owned businesses. She’s also a partner in...
Tags: Deals, Trends, Tech, Venture Capital, San Diego, Biotech, Life Sciences, Tim Scott, Mah, National blog main, San Diego blog main, San Diego top stories, Connect, Ad Astra, Greg McKee, Silvia Mah


The Life, Troubles, and Celgene Legacy of Deal Guru George Golumbeski

George Golumbeski is one of the most prolific dealmakers in the biopharmaceutical world. But the deal that changed his life is a pact he made with himself when he was ten years old.Playing with friends in front of his house in Hampton, VA, he watched his mother drag his dead-drunk father, a U.S. Air Force veteran who did a short stint in Vietnam, out of his car. Pretending to sleep in his bedroom, he’d often hear his parents screaming at each other.“I can’t end up like this,” he remembers think...
Tags: Deals, Ipo, Events, Trends, People, Depression, National, Novartis, Vietnam, Biotech, Illumina, New Enterprise Associates, Life Sciences, University Of Wisconsin, Genentech, UCB


San Diego Life Sciences Roundup: ResMed, Alexandria GradLabs & More

Spring has sprung, and it’s shaping up to be another busy season for San Diego’s life sciences community. As we head into the weekend, crossing our fingers that the seemingly endless rain showers will be replaced by our usual sunshine, here’s a quick rundown of some recent news developments.—ResMed (NYSE: RMD) acquired a South Korea-based medical equipment provider, the company said Friday. Financial terms of the deal weren’t disclosed.The acquisition of privately held HB Healthcare comes less ...
Tags: Startups, Accelerator, South Korea, Trends, Tech, San Diego, Biotech, Life Sciences, Genentech, Roche, Resmed, Alexandria Real Estate Equities, National blog main, San Diego blog main, San Diego top stories, ResMed NYSE


Probing Submicron Protein Aggregation using Asymmetrical Flow Field-Flow Fractionation, AF4, and Light Scattering

The most recent developments by Wyatt in their instrumentation and software have made the full potential of FFF accessible to a wider user base. In this interview, Kim R. Williams and Christoph Johann talk to News-Medical and Life Sciences about the technologies and their research.
Tags: Health, Life Sciences, Wyatt, Kim R Williams, Christoph Johann


Beam Brings In $135M to Turn CRISPR Base Editing into Drugs

Beam Therapeutics made a splash last year when it launched with $87 million to develop medicines that use a more precise form of CRISPR editing. Beam’s promise of CRISPR-based therapeutics that swap out specific bases or “letters” in the genome—something the current generation of CRISPR-based drugs can’t do—has been so enticing to investors that they have put in $135 million in a Series B investment less than a year after the first funding round.CRISPR-Cas9 gene editing, which just last month e...
Tags: Deals, Startups, Boston, Trends, Venture Capital, Biotech, Crispr, Series B, Life Sciences, Broad Institute, Beam, Gene Editing, John Evans, National blog main, Boston blog main, National top stories


Angel Networks Most Active Texas Investors Since 2010, Report Says

Austin — Two angel networks in Texas have been the most active investors in the state since 2010.The Houston Angel Network leads the list with 145 investments during the past nine years, followed by the Central Texas Angel Network in Austin with 144 deals, according to data compiled by Seattle-based PitchBook. Capital Factory, which runs a co-working space abd accelerator in Austin, and also invests in startups, was third on the list with 97 deals. PitchBook compiled the list ahead of South by ...
Tags: Food, Startups, Uber, Accelerator, Gender, Texas, Technology, Washington, Entrepreneurial, Entrepreneurship, Funding, Race, Women, Trends, Startup, Tech


Tasso Gets $6M For Device That Lets Users Self-Collect Blood Samples

Tasso, a Seattle-based startup that is developing an at-home blood sample collection device, announced Tuesday it has raised $6.1 million from investors. The new money will support its effort to launch sales of the device, Tasso OnDemand, in the coming months, and to add staff, Tasso says.Vertical Venture Partners, a Silicon Valley-based investment fund, led the funding round, Tasso says. Other participants included Techstars and Cedars-Sinai, a Los Angeles-based network of hospitals and clinic...
Tags: Deals, Startups, Los Angeles, Trends, Department Of Defense, Vc, Darpa, Food And Drug Administration, Silicon Valley, National Institutes of Health, Fda, Biotech, Seattle, Nih, TechStars, Life Sciences


The growing role of citizen scientists in research

A movement is growing where science is no longer restricted to academics but instead it has become a pursuit for the public in general. Nature lovers have unwittingly been acting as data collectors, especially people that create lists of wildlife they see at home, in the park, or during a hike. Birdwatchers are known for making lists of the bird species they see, and scientists have come to realise that these lists can provide extremely useful information for monitoring animal populations. Throu...
Tags: Books, Texas, Germany, Birds, Biodiversity, North America, Citizen Science, Life Sciences, Bird Watching, Ornithology, Science & Medicine, Earth & Life Sciences, Ameland, Auk, Oystercatcher, Andrew M. Allen


Bio Roundup: Pharma in DC, Bristol-Cel in Trouble, Roche Gets A Spark

Could a shareholder revolt doom the planned marriage of Bristol-Myers Squibb and Celgene? Analysts have hinted at the possibility since the two companies shook hands in January, but the threat became real this week.Bristol (NYSE: BMY) and Celgene (NASDAQ: CELG) have campaignned heavily, starting with a joint presentation by their CEOs at the J.P. Morgan Healthcare Conference in January. Celgene drugs that should come to market the next two years will unlock $15 billion in annual revenue. The co...
Tags: Deals, Startups, Ge, Trends, Merck, Vc, Astrazeneca, Fda, National, Bristol, Novartis, Pfizer, Life Sciences, Clinical Trials, Celgene, Amgen


7 Tips for Biotech Companies Seeking Capital in a Volatile Market

Last year was a remarkable year for biotech companies going public. Not only did an unusually large number of biotech companies go public, but a significant number of early-stage biotech companies went public at premium valuations relative to their later-clinical stage peers.There were approximately 58 biotech IPOs in 2018 (excluding offerings with under $25 million of proceeds) for total gross proceeds of $6.3 billion [1], of which a significant number were early-stage companies — either in pre...
Tags: Deals, Startups, Legal, Law, Trends, Strategy, IPOs, National, Biotech, Financing, Investors, Life Sciences, Boston Xcon, Boulder/Denver Xcon, Detroit Xcon, National Xcon


Rani’s “Robotic Pill” for Biologics Clears First Hurdle in Humans

Swallowing a pill is a convenience that’s not available for all drugs. The cells and proteins in biological therapies can’t survive digestive enzymes, whose role is to break things down. That’s why insulin and other biologics must be injected.But what if there were a pill you could swallow that administers the injection inside your body? That’s the idea behind Rani Therapeutics, a medical technology company that has developed a “robotic pill” and is financially backed by some of world’s biggest...
Tags: Google, Startups, Drugs, San Francisco, Trends, Astrazeneca, Fda, Novartis, Shire, Biotech, Insulin, Medical Device, Alphabet, Life Sciences, Drug Delivery, Clinical Trials


Bristol-Myers’ $74B Celgene Buyout Faces Opposition from Wellington

Bristol-Myers Squibb’s agreement to acquire Celgene for $74 billion is opposed by the New York pharmaceutical company’s largest institutional investor.Wellington Management Group said Wednesday afternoon that while it agrees Bristol should be active in deals that add new science and expand the company’s revenue potential, Wellington “does not believe that the Celgene transaction is an attractive path towards accomplishing this goal.”Shares of Bristol (NYSE: BMY) rose 2.5 percent to $50.25 each ...
Tags: Deals, New York, Drugs, Cancer, Trends, Investing, Bristol, Biotech, Wellington, Life Sciences, Celgene, Bristol-myers Squibb, Bristol Myers, National blog main, New York blog main, New York top stories


Sarepta Touts More Gene Therapy Data, Snaps Up Myonexus For $165M

Sarepta Therapeutics (NASDAQ: SRPT) has been steadily building up its gene therapy capabilities for a few years now, and it took two more steps forward on that front this morning. First, it exercised an option to buy gene therapy startup Myonexus Therapeutics for $165 million. And then it disclosed early human results from the first program to come from the deal, a potential treatment for a form of Limb-Girdle Muscular Dystrophy (LGMD), a progressive, deadly genetic disease with no available tr...
Tags: Deals, Drugs, Boston, Trends, Fda, Biotech, Life Sciences, Clinical Trials, Sarepta, Columbus OH, Gene Therapy, National blog main, National top stories, Boston top stories, Duchenne Muscular Dystrophy, Sarepta Therapeutics


Blackstone, Novartis Start Up Anthos With $250M and a Heart Drug

Blackstone Life Sciences, the biopharma investing arm of private equity firm Blackstone Group, has made its first strike. It has joined with Novartis (NYSE: NVS) to start a new biotech, Anthos Therapeutics, backed with $250 million in cash and rights to an experimental drug originally discovered by the Swiss firm.The Cambridge, MA, startup, Anthos Therapeutics, will use the investment to advance MAA868, a Novartis antibody drug that is meant to treat blood clots by targeting two clotting protei...
Tags: Deals, Startups, Boston, Trends, Vc, Novartis, Biotech, Life Sciences, Blackstone Group, Cambridge MA, National blog main, New York blog main, New York top stories, Boston blog main, National top stories, San Francisco blog main


Ginkgo’s Motif Launches with $90M for Animal-Free Meat & Milk Proteins

Plant-based foods and beverages are getting more grocery store shelf space as consumers increasingly shop for meat and milk alternatives. But these products typically carry premium prices because making proteins in a lab is still far more expensive than conventional agriculture.Motif Ingredients says it can use biotechnology and fermentation to develop proteins that are more affordable and scaleable than those in other meat and milk substitutes. The Boston startup is launching Tuesday with $90 ...
Tags: Deals, Startups, Boston, Trends, Investing, Fda, Biotech, Synthetic Biology, Ginkgo Bioworks, Impossible Foods, Beyond Meat, Cb Insights, Life Sciences, Tom Hayes, Microbes, Archer Daniels Midland Company


Oyster Point Gets $93M To Clear Up Dry Eye With a Nasal Spray

Dry eye disease affects millions of people in the U.S., and while several treatments, mostly eye drops, are available, they all have flaws. An emerging startup called Oyster Point Pharmaceuticals is trying a completely different approach—a nasal spray that coaxes the body into making tears. And the company just got enough cash to get that treatment to market, if its final clinical tests are a success.Oyster Point, a Princeton, NJ startup led by former Ophthotech (NASDAQ: OPHT) executive Jeffrey...
Tags: Deals, Startups, New York, Trends, Vc, Allergan, Shire, New Enterprise Associates, Life Sciences, Ophthotech, Princeton NJ, Versant Ventures, National blog main, New York blog main, New York top stories, Seattle blog main


Ireland: Life Sciences Update: Outlook For 2019 And Post-Brexit Implications - Matheson

2019 has started with a flurry of large M&A deals in the Life Sciences sector.
Tags: News, Ireland, Life Sciences, Matheson


Roche Bets $4.8B on Spark Therapeutics and the Future of Gene Therapy

Roche has agreed to buy Spark Therapeutics for $4.8 billion, the latest strong signal that major pharmaceutical companies are ready to gamble on the promise of gene therapy despite its uncertain commercial prospects.The Swiss pharma giant will pay $114.50 per share, in cash, for Spark (NASDAQ: ONCE), a 122 percent premium to the gene therapy developer’s $51.56 per share closing price on Friday. Both boards have approved the deal, which should close in the second quarter.The acquisition is the l...
Tags: Deals, Trends, Fda, National, Life Sciences, Clinical Trials, Roche, Gene Therapy, UniQure, National blog main, Boston blog main, National top stories, San Francisco blog main, San Francisco top stories, Boston top stories, Spark Therapeutics


Proud papa DSM transfers Biosuccinium to Roquette, dissolves Reverdia JV

In the Netherlands, there is a big change coming for bio-succinic acid production, a graduation of sorts for Biosuccinium. Since 2012, Reverdia’s parent companies — Royal DSM, a global science-based company in Nutrition, Health and Sustainable Living, and Roquette, a global leader in plant-based ingredients for Food, Nutrition and Health markets, — have been producing bio-succinic acid with the trademark name Biosuccinium under a joint venture agreement. But that’s all about to change as they d...
Tags: Top Stories, Netherlands, Belgium, Pbs, Life Sciences, Roquette, Reverdia, DSM, Renewable Fuels Association RFA, Products and Services, Royal DSM, Biosuccinium, Hans van der Sluijs, Cassano Italy, Bio-succinic Acid, Nutrition Health and Sustainable Living


Voyager Therapeutics, AbbVie Add Parkinson’s to Gene Therapy Pact

Voyager Therapeutics and AbbVie, already partners developing gene therapies for Alzheimer’s disease, are now expanding their alliance to include Parkinson’s.AbbVie (NYSE: ABBV) is paying Cambridge, MA-based Voyager (NASDAQ: VYGR) $65 million up front under the new deal. Gene therapies use viruses to carry the genetic instructions into cells. The agreement calls for Voyager to develop the viral vectors that will transport into the brain the genes that code for the production of therapeutic antib...
Tags: Deals, Drugs, Boston, Trends, Alzheimer's Disease, Cambridge, Parkinson's Disease, Abbvie, Biotech, Life Sciences, Clinical Trials, Lewy Body Dementia, Gene Therapy, National blog main, Boston blog main, Boston top stories